Vericel's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Vericel in the third quarter 2026?
Vericel Corporation achieved a return on average equity (ROE) of 9.09 % in its third quarter 2026, this is above VCEL's average return on equity of -38.31%.
Vericel Corporation shareholder's equity over the 12 months ending in its third quarter 2026 are valued at $366 million

ROE has advanced compared to 6.91% in the second quarter 2026, due to net income growth.

Within the Biotechnology & Pharmaceuticals industry 13 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 1805 to 1843.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Equity Change	19.36 %	20.61 %	20.56 %	21.47 %	-
Y / Y Net Income Change	179.09 %	-	-	17.35 %	-
Net Income (TTM) in Millions	33	24	21	17	13
Return On Equity (TTM)	9.09 %	6.91 %	6.41 %	5.17 %	4.3 %
VCEL's Total Ranking	# 1843	# 1805	# 1488	# 1716	#
Equity (TTM) in Millions	384	370	356	355	322
Seq. Equity Change	3.82 %	3.88 %	0.45 %	10.19 %	4.91 %
Seq. Net Income Change	541.93 %	-	-	358.08 %	-

Back to VCEL Management Effectiveness >> VCEL's 5 Years Annual ROE >> Compare VCEL ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 14
Sector	# 158
Overall	# 1843

Return On Equity Statistics
High	Average	Low
6.91 %	-38.31 %	-411.01 %
(Jun 30 2026)		(Jun 30 2014)

VCEL Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	355	292	226	192	170
Y / Y Equity Change	21.47 %	29.22 %	17.52 %	12.79 %	26.96 %
Net Income in Millions	17	10	-3	-17	-7
Y / Y Net Income Change	59.41 %	-	-	-	-
Return On Equity	4.66 %	3.55 %	-1.41 %	-8.69 %	-4.38 %

Back to VCEL Management Effectiveness >> VCEL's 5 Years Annual ROE >> Compare VCEL ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 4.66 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
VCEL's' Return on Equity at Yahoo Finance
VCEL's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for VCEL's Competitors
Subscribers only: Roe for Vericel's Suppliers
Subscribers only: Return On Equity for VCEL's Customers

Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector	ROE
Bioventus Inc	24.60 %
Encompass Health Corporation	24.08 %
Iradimed Corporation	23.90 %
Corcept Therapeutics Inc	22.88 %
Msa Safety Inc	21.79 %
Lantheus Holdings Inc	21.72 %
Iqvia Holdings Inc	21.40 %
Denali Therapeutics Inc	21.40 %
West Pharmaceutical Services Inc	21.08 %
Brightspring Health Services Inc	20.31 %
Healthcare Services Group Inc	20.22 %
Vertex Pharmaceuticals Inc	20.08 %
Ge Healthcare Technologies Inc	20.04 %
Neurocrine Biosciences Inc	19.74 %
Ani Pharmaceuticals Inc	19.70 %
Johnson and Johnson	19.55 %
Beone Medicines Ltd	18.21 %
Pediatrix Medical Group Inc	17.28 %
Kiniksa Pharmaceuticals International Plc	17.27 %
Krystal Biotech Inc	17.02 %
Intuitive Surgical Inc	16.99 %
Ensign Group Inc	16.62 %
Lemaitre Vascular Inc	15.81 %
Stryker Corp	15.61 %
Quest Diagnostics Inc	15.22 %
Regeneron Pharmaceuticals Inc	15.07 %
Bio rad Laboratories Inc	14.07 %
Boston Scientific Corporation	13.75 %
Inspire Medical Systems inc	12.49 %
Haemonetics Corporation	12.07 %

Date modified: 2026-11-06T12:54:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.